Clinical Application of Optical Coherence Tomography in Patients with Non-ST-Elevation Acute Coronary Syndrome Combined with Intermediate Lesions
Objective: This study aimed to evaluate the clinical significance and safety of optical coherence tomography (OCT) in patients with non-ST-elevation acute coronary syndrome (NSTEACS) combined with intermediate lesions.
Methods: Sixty-five NSTEACS patients with intermediate lesions confirmed with coronary angiography at our department were included in this study. Among them,
33 patients received only standardized drug treatment (drug group) and the other 32 patients received percutaneous coronary intervention (PCI) according to the OCT examination based on drug treatment (OCT group). Major adverse cardiovascular events (MACEs), revascularization, success rate of OCT examination, related complications, and other patient situations in the two groups during hospitalization and the 12-month follow-up period were compared.
Results: No death or stroke occurred in either group during hospitalization and follow-up. In the drug treatment group, six patients experienced frequent angina, and five patients with acute myocardial infarction were rehospitalized and underwent PCI procedures. In the OCT group, although two patients underwent repeat revascularization, no additional acute myocardial infarction events occurred. There was a statistically significant difference between the two groups (P < .01). All patients in the OCT group successfully completed the related vessel examination, and 24 patients underwent PCI procedures because of unstable plaque diagnosed with OCT.
Conclusion: OCT-guided PCI is safe and effective for the treatment of patients with NSTEACS combined with intermediate lesions.
Abizaid A, Mintz GS, Pichard AD, et al. 1998. Clinical intravascular ultrasound and quantitative angiographic determinants of the coronary flow reserve before and after percutaneous transluminal coronary angioplasty. Am J Cardiol 82:423-8.
Bech GJ, De Bruyne B, Pijls NH, et al. 2001. Fractional flow reserve to determine the appropriateness of angioplasty in moderate coronary stenosis: a randomized trial. Circulation 103:2928-34.
Bezerra HG, Costa MA, Guagliumi G, Rollins AM, Simon DI. 2009. Intracoronary optical coherence tomography: a comprehensive review clinical and research applications. JACC Cardiovasc Interv 2:1035-46.
Briguori C, Anzuini A, Airoldi F, et al. 2001. Intravascular ultrasound criteria for the assessment of the functional significance of intermediate coronary artery stenosis and comparison with fractional flow reserve. Am J Cardiol 87:136-41.
De Bruyne B, Pijls NH, Kalesan B, et al. 2012. Fractional flow reserve guided PCI versus medical therapy in stable coronary disease. N Engl J Med 367:991-1001.
Di Stefano R, Felice F, Balbarini A. 2009. Angiogenesis as risk factor for plaque vulnerability. Curr Pharm Des 15:1095-1106.
Fernandes MR, Silva GV, Caixeta A, Rati M, de Sousa e Silva NA, Perin EC. 2007. Assessing intermediate coronary lesions: angiographic prediction of lesion severity on intravascular ultrasound. J Invasive Cardiol 19:412-16.
Glaser R, Selzer F, Faxon DP, et al. 2005. Clinical progression of incidental, asymptomatic lesions discovered during culprit vessel coronary intervention. Circulation 111:143-9.
Goldman L, Schafer AI. 2012. Goldman’s Cecil Medicine (24th Edition). Elsevier (Singapore) Pte Ltd. 1:425-53.
Gonzalo N, Tearney GJ, Serruys PW, et al. 2010. Second-generation optical coherence tomography in clinical practice. High-speed data acquisition is highly reproducible in patients undergoing percutaneous coronary intervention. Rev Esp Cardiol 63:893-903.
Honda Y, Fitzgerald PJ. 2008. Frontiers in intravascular imaging technologies. Circulation 117:2024-37.
Huang D, Swanson EA, Lin CP, et al. 1991. Optical coherence tomography. Science 254:1178-81.
Jang IK, Bouma BE, Kang DH, et al. 2002. Visualization of coronary atherosclerotic plaques in patients using optical coherence tomography: comparison with intravascular ultrasound. J Am Coll Cardiol 39:604-9.
Jang IK, Tearney GJ, MacNeill B, et al. 2005. In vivo characterization of coronary atherosclerotic plaque by use of optical coherence tomography. Circulation 111:1551-5.
Jneid H, Anderson JL, Wright RS, et al. 2012. 2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angina/Non-ST-elevation myocardial infarction (updating the 2007 guideline and replacing the 2011 focused update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 126:875-910.
Kitabata H, Tanaka A, Kubo T, et al. 2010. Relation of microchannel structure identified by optical coherence tomography to plaque vulnerability in patients with coronary artery disease. Am J Cardiol 105:1673-8.
Kume T, Akasaka T, Kawamoto T, et al. 2006. Assessment of coronary arterial plaque by optical coherence tomography. Am J Cardiol. 97:1172-5.
Kume T, Akasaka T, Kawamoto T, et al. 2006. Assessment of coronary arterial thrombus by optical coherence tomography. Am J Cardiol 97:1713-17.
Naghavi M, Libby P, Falk E, et al. 2003. From vulnerable plaque to vulnerable patient: a call for new definitions, risk assessment strategies: Part II. Circulation 108:1772-8.
Russell DA, Abbott CR, Gough MJ. 2008. Vascular endothelial growth factor is associated with histological instability of carotid plaques. Br J Surg 95:576-81.
Rzeczuch K, Szajn G, Jankowska E, et al. 2005. Borderline coronary lesions may lead to serious coronary events-long-term outcome in 65 conservatively treated patient. Kardiol Pol 63:50-7.
Takagi A, Tsurumi Y, Ishii Y, Suzuki K, Kawana M, Kasanuki H. 1999. Clinical potential of intravascular ultrasound for physiological assessment of coronary stenosis: relationship between quantitative ultrasound tomography and pressure-derived fractional flow reserve. Circulation 100:250-5.
Tonino PA, De Bruyne B, Pijls NH, et al. 2009. Fractional flow reserve versus angiography for guiding percutaneous coronary intervention. N Engl J Med 360:213-24.
Yabushita H, Bouma BE, Houser SL, et al. 2002. Characterization of human atherosclerosis by optical coherence tomography. Circulation 106:1640-5.
How to Cite
Author Disclosure & Copyright Transfer Agreement
In order to publish the original work of another person(s), The Heart Surgery Forum® must receive an acknowledgment of the Author Agreement and Copyright Transfer Statement transferring to Forum Multimedia Publishing, L.L.C., a subsidiary of Carden Jennings Publishing Co., Ltd. the exclusive rights to print and distribute the author(s) work in all media forms. Failure to check Copyright Transfer agreement box below will delay publication of the manuscript.
A current form follows:
The author(s) hereby transfer(s), assign(s), or otherwise convey(s) all copyright ownership of the manuscript submitted to Forum Multimedia Publishing, LLC (Publisher). The copyright transfer covers the exclusive rights to reproduce and distribute the article and the material contained therein throughout the world in all languages and in all media of expression now known or later developed, including but not limited to reprints, photographic reproduction, microfilm, electronic data processing (including programming, storage, and transmission to other electronic data record(s), or any other reproductions of similar nature), and translations.
However, Publisher grants back to the author(s) the following:
- The right to make and distribute copies of all or part of this work for use of the author(s) in teaching;
- The right to use, after publication in The Heart Surgery Forum, all or part of the material from this work in a book by the author(s), or in a collection of work by the author(s);
- The royalty-free right to make copies of this work for internal distribution within the institution/company that employs the author(s) subject to the provisions below for a work-made-for-hire;
- The right to use figures and tables from this work, and up to 250 words of text, for any purpose;
- The right to make oral presentations of material from this work.
Publisher reserves the right to grant or refuse permission to third parties to republish all or part of the article or translations thereof. To republish, such third parties must obtain written permission from the Publisher. (This is in accordance with the Copyright Statute, United States Code, Title 17. Exception: If all authors were bona fide officers or employees of the U.S. Government at the time the paper was prepared, the work is a “work of the US Government” (prepared by an officer or employee of the US Government as part of official duties), and therefore is not subject to US copyright; such exception should be indicated on signature lines. If this work was prepared under US Government contract or grant, the US Government may reproduce, royalty-free, all or portions of this work and may authorize others to do so, for official US Government purposes only, if the US Government contract or grant so requires.
I have participated in the conception and design of this work and in the writing of the manuscript and take public responsibility for it. Neither this manuscript nor one with substantially similar content under my authorship has been published, has been submitted for publication elsewhere, or will be submitted for publication elsewhere while under consideration by The Heart Surgery Forum, except as described in an attachment. I have reviewed this manuscript (original version) and approve its submission. If I am listed above as corresponding author, I will provide all authors with information regarding this manuscript and will obtain their approval before submitting any revision. I attest to the validity, accuracy, and legitimacy of the content of the manuscript and understand that Publisher assumes no responsibility for the validity, accuracy, and legitimacy of its content. I warrant that this manuscript is original with me and that I have full power to make this Agreement. I warrant that it contains no matter that is libelous or otherwise unlawful or that invades individual privacy or infringes any copyright or other proprietary right. I agree to indemnify and hold Publisher harmless of and from any claim made against Publisher that relates to or arises out of the publication of the manuscript and agree that this indemnification shall include payment of all costs and expenses relating to the defense of any such claim, including all reasonable attorney’s fees.
I warrant that I have no financial interest in the drugs, devices, or procedures described in the manuscript (except as disclosed in the attached statement).
I state that the institutional Human Subjects Committee and/or the Ethics Committee approved the clinical protocol reported in this manuscript for the use of experimental techniques, drugs, or devices in human subjects and appropriate informed consent documents were utilized.
Furthermore, I state that any and all animals used for experimental purposes received humane care in USDA registered facilities in compliance with the “Principles of Laboratory Animal Care” formulated by the National Society for Medical Research and the “Guide for the Care and Use of Laboratory Animals” prepared by the Institute of Laboratory Animal Resources and published by the National Institutes of Health (NIH Publication No. 85-23, revised 1985).